Higher patient adherence to DMDs reduces MS costs

A board to discuss the Multiple Sclerosis modifying drug Copaxone
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Higher patient adherence to DMDs reduces MS costs

Post by MSUK » Wed Nov 30, 2011 12:37 am

Image

Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.

This research was published in the December issue of the Journal of Medical Economics....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Copaxone”